BioTuesdays
Profound Medical

Profound Medical insiders add to holdings 

Profound Medical (NASDAQ:PROF; TSX:PRN) independent lead director, Brian Ellacott, and chairman and CEO, Arun Menawat, purchased additional shares of Profound on Nasdaq after the company’s 2022 first quarter blackout...

NeoTX

NeoTX acquires InterX to boost drug discovery

Closely-held NeoTX of Israel has acquired InterX, a drug discovery company utilizing advanced proprietary tools of biomolecular computation for the discovery and design of novel therapeutic molecules based on Nobel...

Profound Medical

Profound Medical nearly doubles Q1 revenue

Profound Medical (NASDAQ:PROF; TSX:PRN) posted revenue of $1.4-million in the first quarter, up 92%, from $711,000 in the year earlier quarter. In the latest period, the company generated $1.02-million from recurring...